Target Validation Information
TTD ID	T51565
Target Name	Casein kinase II alpha (CSNK2A1)
Type of Target	Clinical trial
Drug Potency against Target		Drug Info	IC50 = 300 nM	[2]
		Drug Info	IC50 = 2000 nM	[4]
		Drug Info	IC50 = 800 nM	[2]
	4,5,6,7-tetrabromo-1H-benzimidazole	Drug Info	IC50 = 1300 nM	[3]
	4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	Drug Info	IC50 = 900 nM	[4]
	5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole	Drug Info	IC50 = 13000 nM	[4]
	AdoC(Dpr)2AlaArg6	Drug Info	IC50 = 17000 nM	[1]
	APIGENIN	Drug Info	IC50 = 800 nM	[4]
	BALANOL	Drug Info	IC50 = 30 nM	[5]
	CGP-029482	Drug Info	IC50 = 390 nM	[4]
	ELLAGIC ACID	Drug Info	IC50 = 40 nM	[4]
References
REF 1	Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
REF 2	Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2. J Med Chem. 2006 Nov 2;49(22):6443-50.
REF 3	Synthesis of new analogs of benzotriazole, benzimidazole and phthalimide--potential inhibitors of human protein kinase CK2. Bioorg Med Chem. 2009 Feb 15;17(4):1573-8.
REF 4	Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3.
REF 5	Synthesis and protein kinase C inhibitory activities of acyclic balanol analogs that are highly selective for protein kinase C over protein kinase A. J Med Chem. 1996 Dec 20;39(26):5215-27.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.